STOCK TITAN

[8-K] HilleVax, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

HilleVax, Inc. filed a Form 8-K to report the results of its 23 June 2025 Annual Meeting of Stockholders. Two routine governance items were presented:

  • Election of three Class III directors – Robert Hershberg, Jeryl Hilleman and Aditya Kohli were each re-elected for three-year terms, receiving roughly 22.0-22.4 million votes for and 1.5-1.8 million votes withheld; 14.5 million broker non-votes were recorded.
  • Ratification of auditor – Ernst & Young LLP was confirmed as the Company’s independent registered public accounting firm for fiscal 2025 with 38.24 million votes for, 0.13 million against and 8,105 abstentions.

No other business or financial information was disclosed. The filing indicates normal, uncontested corporate governance with shareholder support for both board composition and external audit appointment.

HilleVax, Inc. ha presentato un Modulo 8-K per comunicare i risultati della sua Assemblea Annuale degli Azionisti del 23 giugno 2025. Sono stati trattati due punti di governance ordinaria:

  • Rielezione di tre amministratori della Classe III – Robert Hershberg, Jeryl Hilleman e Aditya Kohli sono stati rieletti per un mandato di tre anni, ottenendo circa 22,0-22,4 milioni di voti favorevoli e 1,5-1,8 milioni di voti trattenuti; sono stati registrati 14,5 milioni di voti non espressi dai broker.
  • Ratifica del revisore contabile – Ernst & Young LLP è stata confermata come società di revisione contabile indipendente per l'esercizio fiscale 2025 con 38,24 milioni di voti favorevoli, 0,13 milioni contrari e 8.105 astensioni.

Non sono state divulgate altre informazioni finanziarie o di altro tipo. Il documento indica una governance aziendale ordinaria e non contestata, con il sostegno degli azionisti sia per la composizione del consiglio sia per la nomina del revisore esterno.

HilleVax, Inc. presentó un Formulario 8-K para informar los resultados de su Junta Anual de Accionistas del 23 de junio de 2025. Se presentaron dos asuntos rutinarios de gobernanza:

  • Elección de tres directores de la Clase III – Robert Hershberg, Jeryl Hilleman y Aditya Kohli fueron reelegidos para mandatos de tres años, recibiendo aproximadamente entre 22.0 y 22.4 millones de votos a favor y entre 1.5 y 1.8 millones de votos retenidos; se registraron 14.5 millones de votos no emitidos por corredores.
  • Ratificación del auditor – Ernst & Young LLP fue confirmada como la firma independiente de auditoría pública registrada de la Compañía para el año fiscal 2025, con 38.24 millones de votos a favor, 0.13 millones en contra y 8,105 abstenciones.

No se divulgaron otros asuntos ni información financiera. La presentación indica una gobernanza corporativa normal y no disputada, con apoyo de los accionistas tanto para la composición de la junta como para el nombramiento del auditor externo.

HilleVax, Inc.는 2025년 6월 23일 주주총회 결과를 보고하기 위해 Form 8-K를 제출했습니다. 두 가지 일상적인 거버넌스 안건이 상정되었습니다:

  • 3명 클래스 III 이사 선출 – Robert Hershberg, Jeryl Hilleman, Aditya Kohli가 각각 3년 임기로 재선되었으며, 약 2,200만에서 2,240만 표의 찬성표와 150만에서 180만 표의 기권표를 받았습니다; 중개인 미투표는 1,450만 표가 기록되었습니다.
  • 감사인 승인 – Ernst & Young LLP가 2025 회계연도 독립 등록 공인회계법인으로 확정되었으며, 찬성 3,824만 표, 반대 13만 표, 기권 8,105표가 있었습니다.

기타 사업이나 재무 정보는 공개되지 않았습니다. 제출 서류는 이사회 구성과 외부 감사인 선임에 대해 주주들의 지지를 받는 정상적이고 무쟁점의 기업 거버넌스를 나타냅니다.

HilleVax, Inc. a déposé un formulaire 8-K pour communiquer les résultats de son assemblée annuelle des actionnaires du 23 juin 2025. Deux points de gouvernance de routine ont été présentés :

  • Élection de trois administrateurs de la classe III – Robert Hershberg, Jeryl Hilleman et Aditya Kohli ont été réélus pour des mandats de trois ans, recevant environ 22,0 à 22,4 millions de votes pour et 1,5 à 1,8 million de votes retenus ; 14,5 millions de votes non exprimés par les courtiers ont été enregistrés.
  • Ratification de l’auditeur – Ernst & Young LLP a été confirmé en tant que cabinet d’audit indépendant enregistré de la société pour l’exercice 2025, avec 38,24 millions de votes pour, 0,13 million contre et 8 105 abstentions.

Aucune autre information commerciale ou financière n’a été divulguée. Le dépôt indique une gouvernance d’entreprise normale et non contestée, avec le soutien des actionnaires tant pour la composition du conseil d’administration que pour la nomination de l’auditeur externe.

HilleVax, Inc. hat ein Formular 8-K eingereicht, um die Ergebnisse seiner Hauptversammlung der Aktionäre am 23. Juni 2025 zu melden. Zwei routinemäßige Governance-Punkte wurden vorgestellt:

  • Wahl von drei Direktoren der Klasse III – Robert Hershberg, Jeryl Hilleman und Aditya Kohli wurden jeweils für eine dreijährige Amtszeit wiedergewählt und erhielten etwa 22,0 bis 22,4 Millionen Stimmen dafür sowie 1,5 bis 1,8 Millionen Stimmen, die zurückgehalten wurden; 14,5 Millionen Broker-Non-Votes wurden verzeichnet.
  • Bestätigung des Wirtschaftsprüfers – Ernst & Young LLP wurde als unabhängige eingetragene Wirtschaftsprüfungsgesellschaft für das Geschäftsjahr 2025 bestätigt, mit 38,24 Millionen Stimmen dafür, 0,13 Millionen dagegen und 8.105 Enthaltungen.

Es wurden keine weiteren geschäftlichen oder finanziellen Informationen offengelegt. Die Einreichung deutet auf eine normale, unbestrittene Unternehmensführung mit Aktionärsunterstützung sowohl für die Zusammensetzung des Vorstands als auch für die Bestellung des externen Prüfers hin.

Positive
  • None.
Negative
  • None.

Insights

TL;DR – Routine AGM: directors and auditor approved; neutral impact.

The 2025 AGM produced expected outcomes: the full director slate was re-elected with overwhelming support (≈93% of votes cast) and Ernst & Young was retained with 99.6% approval. There were no shareholder proposals, contested elections or changes to capital structure. Consequently, risk profile, strategic direction and financial outlook remain unchanged. Investors typically view such filings as housekeeping items, so minimal market reaction is anticipated.

HilleVax, Inc. ha presentato un Modulo 8-K per comunicare i risultati della sua Assemblea Annuale degli Azionisti del 23 giugno 2025. Sono stati trattati due punti di governance ordinaria:

  • Rielezione di tre amministratori della Classe III – Robert Hershberg, Jeryl Hilleman e Aditya Kohli sono stati rieletti per un mandato di tre anni, ottenendo circa 22,0-22,4 milioni di voti favorevoli e 1,5-1,8 milioni di voti trattenuti; sono stati registrati 14,5 milioni di voti non espressi dai broker.
  • Ratifica del revisore contabile – Ernst & Young LLP è stata confermata come società di revisione contabile indipendente per l'esercizio fiscale 2025 con 38,24 milioni di voti favorevoli, 0,13 milioni contrari e 8.105 astensioni.

Non sono state divulgate altre informazioni finanziarie o di altro tipo. Il documento indica una governance aziendale ordinaria e non contestata, con il sostegno degli azionisti sia per la composizione del consiglio sia per la nomina del revisore esterno.

HilleVax, Inc. presentó un Formulario 8-K para informar los resultados de su Junta Anual de Accionistas del 23 de junio de 2025. Se presentaron dos asuntos rutinarios de gobernanza:

  • Elección de tres directores de la Clase III – Robert Hershberg, Jeryl Hilleman y Aditya Kohli fueron reelegidos para mandatos de tres años, recibiendo aproximadamente entre 22.0 y 22.4 millones de votos a favor y entre 1.5 y 1.8 millones de votos retenidos; se registraron 14.5 millones de votos no emitidos por corredores.
  • Ratificación del auditor – Ernst & Young LLP fue confirmada como la firma independiente de auditoría pública registrada de la Compañía para el año fiscal 2025, con 38.24 millones de votos a favor, 0.13 millones en contra y 8,105 abstenciones.

No se divulgaron otros asuntos ni información financiera. La presentación indica una gobernanza corporativa normal y no disputada, con apoyo de los accionistas tanto para la composición de la junta como para el nombramiento del auditor externo.

HilleVax, Inc.는 2025년 6월 23일 주주총회 결과를 보고하기 위해 Form 8-K를 제출했습니다. 두 가지 일상적인 거버넌스 안건이 상정되었습니다:

  • 3명 클래스 III 이사 선출 – Robert Hershberg, Jeryl Hilleman, Aditya Kohli가 각각 3년 임기로 재선되었으며, 약 2,200만에서 2,240만 표의 찬성표와 150만에서 180만 표의 기권표를 받았습니다; 중개인 미투표는 1,450만 표가 기록되었습니다.
  • 감사인 승인 – Ernst & Young LLP가 2025 회계연도 독립 등록 공인회계법인으로 확정되었으며, 찬성 3,824만 표, 반대 13만 표, 기권 8,105표가 있었습니다.

기타 사업이나 재무 정보는 공개되지 않았습니다. 제출 서류는 이사회 구성과 외부 감사인 선임에 대해 주주들의 지지를 받는 정상적이고 무쟁점의 기업 거버넌스를 나타냅니다.

HilleVax, Inc. a déposé un formulaire 8-K pour communiquer les résultats de son assemblée annuelle des actionnaires du 23 juin 2025. Deux points de gouvernance de routine ont été présentés :

  • Élection de trois administrateurs de la classe III – Robert Hershberg, Jeryl Hilleman et Aditya Kohli ont été réélus pour des mandats de trois ans, recevant environ 22,0 à 22,4 millions de votes pour et 1,5 à 1,8 million de votes retenus ; 14,5 millions de votes non exprimés par les courtiers ont été enregistrés.
  • Ratification de l’auditeur – Ernst & Young LLP a été confirmé en tant que cabinet d’audit indépendant enregistré de la société pour l’exercice 2025, avec 38,24 millions de votes pour, 0,13 million contre et 8 105 abstentions.

Aucune autre information commerciale ou financière n’a été divulguée. Le dépôt indique une gouvernance d’entreprise normale et non contestée, avec le soutien des actionnaires tant pour la composition du conseil d’administration que pour la nomination de l’auditeur externe.

HilleVax, Inc. hat ein Formular 8-K eingereicht, um die Ergebnisse seiner Hauptversammlung der Aktionäre am 23. Juni 2025 zu melden. Zwei routinemäßige Governance-Punkte wurden vorgestellt:

  • Wahl von drei Direktoren der Klasse III – Robert Hershberg, Jeryl Hilleman und Aditya Kohli wurden jeweils für eine dreijährige Amtszeit wiedergewählt und erhielten etwa 22,0 bis 22,4 Millionen Stimmen dafür sowie 1,5 bis 1,8 Millionen Stimmen, die zurückgehalten wurden; 14,5 Millionen Broker-Non-Votes wurden verzeichnet.
  • Bestätigung des Wirtschaftsprüfers – Ernst & Young LLP wurde als unabhängige eingetragene Wirtschaftsprüfungsgesellschaft für das Geschäftsjahr 2025 bestätigt, mit 38,24 Millionen Stimmen dafür, 0,13 Millionen dagegen und 8.105 Enthaltungen.

Es wurden keine weiteren geschäftlichen oder finanziellen Informationen offengelegt. Die Einreichung deutet auf eine normale, unbestrittene Unternehmensführung mit Aktionärsunterstützung sowohl für die Zusammensetzung des Vorstands als auch für die Bestellung des externen Prüfers hin.

false000188801200018880122025-06-232025-06-23

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2025

 

 

HILLEVAX, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41365

85-0545060

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

321 Harrison Avenue

 

Boston, Massachusetts

 

02118

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 617 213-5054

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

HLVX

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07.

Submission of Matters to a Vote of Security Holders.

On June 23, 2025, HilleVax, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, stockholders voted on the matters disclosed in the Company’s definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on April 30, 2025. The final voting results for the matters submitted to a vote of stockholders were as follows:

Proposal No. 1 - Election of Class III Directors

At the Annual Meeting, the Company’s stockholders elected the persons listed below as Class III directors for a three-year term expiring at the Company’s 2028 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified:

 

 

 

 

 

 

 

 

 

 

 

 

Directors

Votes For

Withheld

Broker Non-Votes

Robert Hershberg, M.D., Ph.D.

22,286,355

 

 

 

1,574,443

 

 

 

14,522,437

 

Jeryl Hilleman

22,039,977

 

 

 

1,820,821

 

 

 

14,522,437

 

Aditya Kohli, Ph.D.

 

22,355,721

 

 

 

1,505,077

 

 

 

14,522,437

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm

At the Annual Meeting, the Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2025:

 

 

 

 

 

Votes For

Votes Against

Abstentions

38,241,645

 

133,485

 

8,105


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

HilleVax, Inc.

 

 

 

 

Date:

June 25, 2025

By:

/s/ Paul S. Bavier

 

 

 

Name: Paul S. Bavier
Title: General Counsel and Chief Administrative Officer

 


FAQ

What matters were voted on at HLVX's 2025 Annual Meeting?

Shareholders voted on two items: election of three Class III directors and ratification of Ernst & Young LLP as independent auditor.

Were HilleVax (HLVX) directors re-elected?

Yes. Robert Hershberg, Jeryl Hilleman and Aditya Kohli were each re-elected for three-year terms ending in 2028.

How many votes supported Ernst & Young as HLVX's auditor?

38,241,645 votes were cast in favor, representing 99.6% support.

Did any proposals fail at HLVX's 2025 AGM?

No. Both proposals—director elections and auditor ratification—passed by large margins.

Does the Form 8-K include financial or earnings data for HLVX?

No. The filing covers only AGM voting results and contains no financial metrics.
HilleVax, Inc.

NASDAQ:HLVX

HLVX Rankings

HLVX Latest News

HLVX Latest SEC Filings

HLVX Stock Data

94.19M
30.11M
17.11%
72.72%
3.25%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON